Brooks Laboratories share news, announcements and annual reports
NSE: BROOKSBSE: 533543Pharmaceuticals & BiotechnologySmall Cap
Brooks Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2011
Last close ₹60.56down ₹3.28 (5.14%)BSE ₹60.85
Share price at the NSE close on 30 Oct 2026. Previous close ₹63.84.
30 Oct: open ₹65.80, high ₹66.00, low ₹59.70
52-week range of traded prices to 30 Oct 2026
₹36.30Low, 30 Mar 2026₹116.00High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹178 Cr2,450th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.45
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 54,79557.7% delivered
Brooks Laboratories disputes and clarifications
21 filed, newest first.
Oct 2026
12 Oct · Legal
Significant movement in price has been observed in Brooks Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Apr 2026
2 Apr · Legal
The exchange asked on 1 Apr 2026
Mar 2025
4 Mar · Legal
Exchange has sought clarification from Brooks Laboratories Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is awaited.
Dec 2023
27 Dec · Legal
The exchange asked on 27 Dec 2023
Mar 2023
20 Mar · Legal
The exchange asked on 20 Mar 2023
Apr 2022
11 Apr · Legal
The exchange asked on 8 Apr 2022
Oct 2021
Sep 2021
30 Sep · Legal
Exchange has sought clarification from Brooks Laboratories Limited with respect to announcement dated 29-Sep-2021, regarding Appointment of Mrs Kaushalya Singh as Executive Director of the company w.e.f. September 29, 2021. On basis of above the Company is required to clarify following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.The response of the Company is awaited.
Jul 2021
6 Jul · Legal
Exchange has sought clarification from Brooks Laboratories Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Aug 2020
3 Aug · Legal
Exchange has sought clarification from Brooks Laboratories Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Statement of Cash Flow not submitted The response of the Company is awaited.
Jan 2020
7 Jan · Legal
The exchange asked on 6 Jan 2020
Mar 2019
5 Mar · Legal
The exchange asked on 26 Feb 2019
Mar 2018
19 Mar · Legal
Exchange has sought clarification from Brooks Laboratories Limited with respect to announcement dated 15-Mar-2018, regarding "Credit Rating". On basis of above the Company is required to clarify following: 1. In case of downward rating, the disclosure may include reasons published by rating agency for such downward rating.The response of the Company is awaited.
Jan 2015
14 Jan · Legal
Exchange had sought clarification from Brooks Laboratories Limited with respect to a news item captioned "Brooks Labs, honchos fined Rs. 12 cr". The Company has clarified that "As per SEBI website, the Adjudicating Officer has passed an Order dated January 12, 2015 against the Company and its directors/officials. As per the Order, a penalty of Rs 1 crore is imposed on the Company and Rs 10.8 crores on five other entities comprising of three directors and two former officials of the Company. We have yet not been served with the copy of the said Order either by post or email. We may point out that the Order is culmination of the Ad-Interim Ex-Parte Order passed against the Company on December 28, 2011 and a subsequent Confirmatory Order in this regard on July 09, 2013, which are already in public domain. We would like to submit that we do not agree with the findings of the Order and we would be contesting the same before Securities Appellate Tribunal in due course".13 Jan · Legal
Exchange has sought clarification from Brooks Laboratories Limited with respect to recent news item captioned "Brooks Labs, honchos fined Rs.12 cr". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
4 Dec · Legal
Exchange had sought clarification from Brooks Laboratories Limited with respect to a news item captioned "Orders passed against DLF, 7 others". The Company has clarified that "It is a matter of record that SEBI had passed an Ad Interim Ex-Parte Order against the Company on December 28, 2011. Subsequently, SEBI passed a Confirmatory Order in this regard on July 09, 2013. Apart from the aforesaid Orders, no other Order has been passed against the Company by SEBI. We would like to submit that this is not a new development as the aforesaid Orders were passed some time ago and the information is already in public domain".3 Dec · Legal
Exchange has sought clarification from Brooks Laboratories Limited with respect to recent news item captioned "Orders passed against DLF, 7 others". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.